1 |
NCT03125460 |
Recruiting |
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer |
|
- Device: Xpert Bladder Cancer Monitor
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Comparison to histology for positive or suspicious cystoscopy
- Comparison to UroVysion and urine cytology
|
530 |
All |
40 Years to 100 Years (Adult, Senior) |
NCT03125460 |
170 |
|
December 2016 |
December 2018 |
December 2018 |
April 24, 2017 |
February 1, 2018 |
|
- PAVA
Palo Alto, California, United States - The Urology Center of Colorado, P.C.
Denver, Colorado, United States - Urology Associates, P.C.
Englewood, Colorado, United States - (and 14 more...)
|
2 |
NCT02177695 |
Recruiting |
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer |
|
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Methotrexate
- (and 3 more...)
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The relationship of dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)- and gemcitabine+cisplatin (GC)- specific CO-eXpression ExtrapolatioN (COXEN) scores.
- Predictability of the CO-eXpression ExtrapolatioN (COXEN) score to direct which of the two regimens the patient should receive: gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)
- Overall survival
- (and 2 more...)
|
184 |
All |
18 Years and older (Adult, Senior) |
NCT02177695 |
S1314 NCI-2014-00850 U10CA180888 |
COXEN |
July 2014 |
February 2020 |
October 2022 |
June 30, 2014 |
July 13, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - University of Arizona Cancer Center at Saint Joseph's
Phoenix, Arizona, United States - (and 564 more...)
|
3 |
NCT02844816 |
Recruiting |
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
- Recurrent Bladder Urothelial Carcinoma
- Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
- (and 2 more...)
|
- Drug: Atezolizumab
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response rate in the subset of patients with carcinoma in situ (CIS) based on biopsy
- Event-free survival (EFS)
- Event-free survival (EFS) in the Ta/T1 subset
- (and 5 more...)
|
148 |
All |
18 Years and older (Adult, Senior) |
NCT02844816 |
NCI-2016-01104 S1605 U10CA180888 |
|
February 7, 2017 |
February 28, 2019 |
February 28, 2019 |
July 26, 2016 |
April 17, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 198 more...)
|
4 |
NCT00579514 |
Recruiting |
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients |
- Breast Cancer
- Bladder Cancer
- Kidney Cancer
- (and 4 more...)
|
- Genetic: PCR/PCR/LDR Strategy
|
Interventional |
Not Applicable |
- Memorial Sloan Kettering Cancer Center
- Columbia University
- Weill Medical College of Cornell University
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- To collect anonymized germline DNA from patients with breast, bladder, kidney, lung, colon, testicular, prostate, lymphoid, ovarian or head and neck cancers, as well as patients with multiple primary cancers, from select New York City ethnic groups.
- To analyze DNA samples from matched non-cancer individuals of the same ethnic groups available as part of the AMDeC-sponsored New York Cancer Study.
|
2530 |
All |
Child, Adult, Senior |
NCT00579514 |
00-014 |
|
March 2000 |
March 2020 |
March 2020 |
December 24, 2007 |
October 4, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
5 |
NCT03288545 |
Recruiting |
A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103) |
- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms
- Urologic Neoplasms
- (and 4 more...)
|
- Drug: enfortumab vedotin
- Drug: pembrolizumab
- Drug: atezolizumab
|
Interventional |
Phase 1 |
- Astellas Pharma Global Development, Inc.
- Seattle Genetics, Inc.
- Astellas Pharma Inc
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicity (DLT)
- Type, incidence, severity, seriousness, and relatedness of adverse events
- Type, incidence, and severity of laboratory abnormalities
- (and 14 more...)
|
85 |
All |
18 Years and older (Adult, Senior) |
NCT03288545 |
SGN22E-002 |
|
October 11, 2017 |
September 2019 |
September 2020 |
September 20, 2017 |
April 6, 2018 |
|
- Stanford Cancer Center / Blood & Marrow Transplant Program
Stanford, California, United States - University of Colorado Hospital / University of Colorado
Aurora, Colorado, United States - Yale Cancer Center
New Haven, Connecticut, United States - (and 8 more...)
|
6 |
NCT03244384 |
Recruiting |
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer |
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
|
- Other: Clinical Observation
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Disease-free survival
- Overall survival in PD-L1 positive and negative patients
- Disease-free survival in PD-L1 positive and negative patients
|
739 |
All |
18 Years and older (Adult, Senior) |
NCT03244384 |
NCI-2017-01425 A031501 U10CA180821 |
|
September 21, 2017 |
February 28, 2019 |
February 28, 2019 |
August 9, 2017 |
April 17, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 499 more...)
|
7 |
NCT01631552 |
Recruiting |
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers |
- Colorectal Cancer
- Gastric Adenocarcinoma
- Esophageal Cancer
- (and 15 more...)
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT01631552 |
IM-T-IMMU-132-01 |
|
February 2013 |
June 2018 |
June 2018 |
June 29, 2012 |
June 14, 2017 |
|
- University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States - Yale University School of Medicine
New Haven, Connecticut, United States - Helen F. Graham Cancer Center
Newark, Delaware, United States - (and 9 more...)
|
8 |
NCT02465060 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- (and 47 more...)
|
- Drug: Adavosertib
- Drug: Afatinib
- Drug: Binimetinib
- (and 21 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment
- Overall survival, evaluated specifically for each drug (or step)
- Progression free survival
- Time to progression
|
6452 |
All |
18 Years and older (Adult, Senior) |
NCT02465060 |
NCI-2015-00054 EAY131 U10CA180820 U24CA196172 |
|
August 12, 2015 |
June 30, 2022 |
|
June 8, 2015 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 1211 more...)
|